Featured
What specialists really think of MSLs
While most specialists view MSLs positively almost a third describe their interactions as average or poor and almost one in three can't spot the difference between an MSL and Sales Rep
Regulatory & Reimbursement
Eczema drug back on PBS listing track
Following an extended back-and-forth with the PBAC, this pharma appears to be progressing its new treatment towards a PBS listing
Pipeline & Intellectual Property
Smaller dose behind bigger profits?
Company catches up with how patients who are using this drug in the real world by kicking off a new trial and the upside could be a hike in profits
Industry & Companies
'Totally unacceptable': Pharma slammed by UK watchdog
Slapped with the most serious Code of Conduct breach and reprimanded for a "significant failure" on transparency
Industry & Companies
CSL raises $2B but it could come at a cost
The new loans carry an interest rate significantly higher than the ones being replaced
Regulation & Legal
TGA cracks down dishing $127K in fines
Australia's regulator has handed out a dozen fines for offences involving Eli Lilly's Mounjaro and Olumiant, along with a number of other drugs
Pipeline & Intellectual Property
Archrivals face battle with a new enemy
This newcomer is set to disrupt a longtime rivalry between two Big Pharmas in a highly competitive space after stunning phase 3 results
Featured
Drugs slated to exit Australia in 2027
Two well-known cancer drugs that historically generated around $50 million in annual sales each will be removed from the Australian market in the first half of 2027
Jobs & Workplace
Talent on the move: who's up, who's new, who's left
With only one quarter remaining of 2026, companies are already lining up their talent for next year with a flurry of promotions and new hires
Regulatory & Reimbursement
Why this therapy must move to an earlier line
Half of the cancer patients who received a one-shot therapy remain progression free after five years, follow-up results show
Pipeline & Intellectual Property
CSL makes $1.7B bet on first-in-class hopeful
Exclusive global partnership to co-develop and co-promote a potential game-changing therapy across a range of kidney and liver diseases
Jobs
Featured
Jobs go as pharma restructure hits Australia
While the exact number of roles or business functions impacted has not been officially disclosed, it’s understood redundancies have hit the commercial team
Regulatory & Reimbursement
Aussie first hits lucrative market
Roche is delivering the first innovative solution of its kind to Australian patients with the company already heading to the PBAC for reimbursement
Regulatory & Reimbursement
Fourth sponsor enters hot biosimilar market
A new competitor to what was once the top-selling drug on the PBS plus approval for the first generic of a drug first registered in Australia in 1991
Industry & Companies
Trial failure throws future of pharma into doubt
ASX-listed biopharma has gone into voluntary administration, seeking to preserve its intellectual property after a catastrophic Phase 3 trial failure
Industry & Companies
Number of Best Workplaces in Aussie Pharma doubles
Now in its third year, the industry-specific list, compiled by Great Places to Work has doubled in size, with 10 companies making the cut in 2026
Regulatory & Reimbursement
First rival but no price cut for $20M drug
Even though three 'first new brands' hit onto the PBS at the start of October in competition with this $20M drug, there's been no price cut
Jobs & Workplace
Novartis General Manager departs
Well-known GM for New Zealand says he's looking forward to spending time with family, recharging, and exploring what's next
Regulatory & Reimbursement
First rival triggers price cut for $70M drug
Biosimilar maker picks up three reimbursements for October, one of which triggered a statutory 25 per cent price cut for a $70M-a-year drug
Pipeline & Intellectual Property
Has Lilly moved the goal posts in weight loss?
Impressive new trial results may have changed what weight loss drugs need to achieve to grab a slice of the market
Regulatory & Reimbursement
Longer US life... but what about Australia?
An Australian-developed drug forecast to earn half a billion this year just got another five years of patent protection in the US but plans for Australian registration are still missing
Regulation & Legal
Info sheet breaches Aussie Code
Materials informing HCPs of a change to PBS criteria were worded in a way that breached the Code of Conduct, an MA Committee has determined
Regulatory & Reimbursement
Drug approvals slide in Australia
After a mammoth year of prescription drug approvals in 2025, the registration of both new drugs and new indications for existing medicines fizzles
Pipeline & Intellectual Property
AZ buys in before Summit's peak?
In what could be a savvy move, AZ has acquired more than 10 per cent of Summit Therapeutics ahead of much-hyped trial results
Regulatory & Reimbursement
October listing a win for complex condition
A treatment that provides a much-needed alternative option for people with atopic dermatitis has hit the PBS
- Industry & Companies Who's Australia's Most Trusted (and Distrusted) pharma?
- Industry & Companies Patients pick ANZ's best pharma
- Jobs & Workplace Tax reform could force Aussie jobs overseas
- Regulatory & Reimbursement Time to use the C-word for multiple myeloma?
- Industry & Companies Biogen staff spread early Christmas cheer
- Regulatory & Reimbursement Govt trumpets groundbreaking cancer results
- Industry & Companies Women in pharma hit milestone
- Industry & Companies Trump nabs secret slice of Aussie drug prices
- Regulation & Legal TGA goes to court over prescription meds
- Sales, Marketing & Public Relations Lilly hit by health industry backlash
